Developer docs
API playgroundTry for free, no card

Search company profiles

Constructive Bio

Full company profile

uuid0000dai

Namestring
Constructive Bio
Legal namestring
Constructive Biology Limited
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Constructive Bio (legal entity: Constructive Biology Limited) is a Cambridge, UK-based synthetic biology company spun out of the MRC Laboratory of Molecular Biology in 2021 by Professor Jason Chin FRS. The company has built a proprietary platform that combines whole-genome synthesis (Syn61, Syn57, CONEXER) with engineered translation machinery to incorporate non-canonical amino acids (ncAAs) into peptides and proteins at site-specific positions. Its flagship commercial offering, BioForge, is a fermentation platform that uses genetically recoded organisms (GROs) to manufacture peptide therapeutics — including DPPIV-resistant GLP-1 agonists and candidates for liver fibrosis and cardiometabolic disease — as a scalable, sustainable alternative to solid-phase peptide synthesis (SPPS). The IP base is anchored by exclusive licenses from MRC LMB, most recently including the tRNA Display technology licensed in June 2025.

The company's commercial model is B2B and enterprise-oriented, targeting large and mid-size pharmaceutical companies as the primary segment and biotech / life sciences companies as a secondary segment. Go-to-market is executed through direct field sales and strategic partnerships rather than self-serve or consumer channels. Named collaborations include RxCelerate (biologic therapeutic candidates, announced November 2025), the Ellison Institute's Generative Biology Institute (programmable biology, October 2025), Camena Bioscience and the Max-Planck Institute (ARIA-funded synthetic chloroplast genomes, August 2025), and CPI (peptide manufacturing process development). Revenue is expected to come from three streams: platform licensing and partnerships, out-licensing or sale of proprietary biologic candidates, and fermentation-based peptide manufacturing, none of which have produced commercial revenue to date.

Constructive Bio is pre-revenue and venture-backed, having raised approximately $75M in total: a $15M seed in August 2022 led by Ahren, and a $58M Series A in September 2024 led by Ahren, OMX Ventures, and Paladin Capital Group with participation from Fine Structure Ventures, ND Capital, and Jonathan Milner. The team is approximately 30 people headquartered at the 11,000 sq ft "The Recodery" facility in Whittlesford, Cambridge. The leadership team combines scientific founders (Jason Chin as CSO), operational executives (Ola Wlodek as CEO, Solange Bullukian as CFO, Paul Wallace as CBO, Linda Ramirez-Eaves as CLO), and a board that includes Nobel Laureate Sir Gregory Winter and biopharma operator Jim Weissman. Recognition includes the 2026 Heinrich Wieland Prize, the 2025 SynBioBeta Impact Award, and inclusion as a Nature Biotechnology Editor's Pick.

Short descriptiontext

Constructive Bio is a Cambridge, UK synthetic biology company that rewrites genetic codes via genetically recoded organisms to manufacture peptide and protein therapeutics containing non-canonical amino acids. It serves pharmaceutical and biotech customers through its BioForge fermentation platform, platform licensing, and co-development partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWhittlesford, United Kingdom
HQ citystring
Whittlesford
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
synthetic genomics, peptide therapeutics, genetic code expansion, non-canonical amino acids, biologics manufacturing
Industry4 codes
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Synthetic Biology / Peptide Therapeutics Manufacturing
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Platform Licensing and Partnerships
TypeLicensing Royalties
Description

Revenue anticipated from licensing the synthetic genomics platform and engineered translation machinery to pharmaceutical and biotech partners for drug discovery and development programs, including GLP-1 therapeutics. Partnerships structured as co-development agreements, collaboration fees, and milestone-based payments.

2Biologic Therapeutic Candidates
TypeLicensing Royalties
Description

Revenue generation through the development and out-licensing or sale of proprietary biologic therapeutic candidates generated using the platform, including peptides and proteins incorporating non-canonical amino acids.

3Fermentation-Based Peptide Manufacturing
TypeLicensing Royalties
Description

Sustainable, fermentation-based manufacturing of peptides and proteins as an alternative to traditional solid-phase peptide synthesis (SPPS), targeting the $80B+ peptide therapeutics market.

Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Constructive Bio develops a synthetic genomics platform that uses genetically recoded organisms (notably Syn61, the world's first fully synthetic recoded genome) and engineered translation machinery to incorporate non-canonical amino acids into peptides and proteins. Its flagship offering, BioForge, is a fermentation-based manufacturing platform that produces peptide and protein therapeutics at industrial scale as a sustainable alternative to chemical solid-phase peptide synthesis, with co-development partnerships and platform licensing for pharmaceutical and biotech customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Platform enables exploration of hundreds of millions of non-canonical amino acid-containing peptide and protein variants for therapeutic discovery.
+2 more records
Product overview1 text field

Constructive Bio operates as a platform company built on two integrated technology pillars: Synthetic Genomics (whole-genome synthesis and recoding) and Engineered Translation (non-canonical amino acid incorporation). The flagship product is BioForge, a fermentation platform that manufactures peptide therapeutics with non-canonical amino acids using proprietary recoded organisms. The platform is underpinned by foundational technologies including Syn61 (the world's first fully synthetic recoded genome) and tRNA Display technology. A Partner Portal provides existing partners with project management and document access tools. Together, these products enable the biological production of peptides, proteins, macrocycles, and non-protein polymers with chemistries that natural biology cannot access.

Product and service5 records
1BioForge
CategoryPeptide Therapeutics Manufacturing
Description

Proprietary fermentation platform that uses engineered organisms with recoded genomes to manufacture peptide therapeutics containing non-canonical amino acids at industrial scale through biological fermentation rather than chemical synthesis. Sold/licensed to pharmaceutical partners.

2Synthetic Genomics Platform
CategorySynthetic Genomics
Description

Platform for whole-genome synthesis enabling assembly of large DNA segments exceeding 200 kb with verified sequence accuracy and creation of megabase-scale custom DNA in E. coli, forming the foundation for creating recoded organisms used by pharmaceutical and biotech partners.

3Engineered Translation Platform
CategoryEngineered Translation
Description

Platform for engineered protein translation that incorporates non-canonical amino acids (ncAAs) into peptides and proteins by reprogramming the genetic code of cells, creating biofactories for novel biopolymers. Provided to pharmaceutical and biotech partners for therapeutic development.

4tRNA Display Technology
CategoryProtein Engineering Technology
Description

Exclusively licensed technology from MRC LMB enabling rapid and accurate selection of enzymes (tRNA synthetases) for integrating non-canonical amino acids into peptides and proteins, overcoming a major barrier in protein engineering. Used by Constructive Bio and its partners for therapeutic candidate discovery.

5Partner Portal
CategoryPartner Services
Description

Secure partner access portal providing real-time project status and milestone tracking, document library with reports and agreements, and direct support from dedicated project teams. Provided to pharmaceutical and biotech partners engaged in co-development programs.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-18
Description

Strategic partnership with RxCelerate, a specialized biologics contract research organization, for the advancement of biologic therapeutic candidates. RxCelerate provides integrated discovery and preclinical development services, supporting Constructive Bio's pipeline of non-canonical amino acid-containing peptide and protein therapeutics.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

Collaboration with the Ellison Institute's Generative Biology Institute, a leading academic center focused on applying generative and synthetic biology approaches to biomedical research. The partnership leverages combined expertise in synthetic genomics and generative biology for novel therapeutic discovery.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-01
Description

AR

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-01
Description

Three-party ARIA-funded collaboration between Constructive Bio, Camena Bioscience, and the Max-Planck Institute focused on advancing synthetic genomics and genome synthesis technologies. The partnership combines Constructive Bio's synthetic recoded genome platform, Camena Bioscience's DNA synthesis capabilities, and the Max-Planck Institute's research expertise.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Partnership with CPI, a UK-based technology innovation center, funded by Innovate UK, focused on developing and advancing peptide manufacturing processes. The collaboration supports Constructive Bio's fermentation-based manufacturing capabilities as a sustainable alternative to traditional solid-phase peptide synthesis.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Sutro operates a cell-free protein synthesis platform that incorporates non-canonical amino acids for site-specific conjugation of ADCs and other therapeutics. It is the closest direct peer to Constructive Bio in ncAA-incorporating biologic platforms targeting pharma partners, though Sutro uses a cell-free system rather than recoded organisms.

2Ambrx
TypeBroad incumbent
Description

Ambrx pioneered site-specific incorporation of non-canonical amino acids into proteins for ADCs and other biologics and was acquired by Johnson & Johnson. As the most clinically advanced ncAA-biologics platform, it is the benchmark Constructive Bio must beat on clinical and commercial proof points, even though Ambrx is now embedded in a much larger pharma.

TypeDirect peer
Description

Codexis engineers proteins (notably enzymes and biotherapeutics) using directed evolution and platform approaches sold into pharma and industrial biotech customers. It is comparable to Constructive Bio as a protein-engineering platform company monetized through licensing and partnerships, with a similar B2B enterprise model.

TypeDirect peer
Description

Synaffix licenses site-specific ADC conjugation chemistries, including approaches based on non-canonical amino acid incorporation, and was acquired by Lonza. Its licensing-and-platform model for ncAA-enabled biologics is closely analogous to Constructive Bio's anticipated licensing/partnership motion in the ADC and bioconjugate space.

TypeBroad incumbent
Description

Ginkgo is a large, publicly listed synthetic biology platform company offering organism engineering services across pharma, agriculture, and industrial biotech. It is a broader incumbent comparable to Constructive Bio on the 'engineered organism as a service' axis, though its scope and capital base are far larger.

TypeBroad incumbent
Description

Twist provides high-throughput DNA synthesis that underpins synthetic biology workflows. Constructive Bio's CONEXER genome synthesis platform competes with and depends on suppliers like Twist; the two are comparable as DNA/gene synthesis infrastructure providers serving biotech customers.

TypeEmerging player
Description

Generate applies generative AI and machine learning to design novel protein therapeutics, sitting at the intersection of computational biology and biologics discovery. It is comparable to Constructive Bio as an emerging platform company creating new therapeutic proteins, but with an AI-driven rather than genome-recoding approach.

TypeEmerging player
Description

Cradle uses AI/ML to engineer proteins and biologics, offering a software-and-services platform for protein design. It overlaps with Constructive Bio on the 'novel therapeutic protein design' axis but does not compete on the fermentation/ncAA manufacturing layer.

TypeEmerging player
Description

Camena is a DNA synthesis company and an actual ARIA-funded collaboration partner of Constructive Bio. It is a relevant emerging peer because both companies operate at the synthetic DNA / genome synthesis infrastructure layer feeding into engineered organisms.

TypeRegional player
Description

Crinetics is a US-based clinical-stage peptide therapeutics company focused on endocrine and metabolic diseases including GLP-1-related targets. While not a platform peer, it is relevant as a downstream comparability point for the peptide therapeutic indications Constructive Bio's BioForge is targeting.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Constructive Bio

Synthetic Biology / Peptide Therapeutics Manufacturingconstructive.bio

Constructive Bio is a Cambridge, UK synthetic biology company that rewrites genetic codes via genetically recoded organisms to manufacture peptide and protein therapeutics containing non-canonical amino acids. It serves pharmaceutical and biotech customers through its BioForge fermentation platform, platform licensing, and co-development partnerships.

What Constructive Bio does

Constructive Bio (legal entity: Constructive Biology Limited) is a Cambridge, UK-based synthetic biology company spun out of the MRC Laboratory of Molecular Biology in 2021 by Professor Jason Chin FRS. The company has built a proprietary platform that combines whole-genome synthesis (Syn61, Syn57, CONEXER) with engineered translation machinery to incorporate non-canonical amino acids (ncAAs) into peptides and proteins at site-specific positions. Its flagship commercial offering, BioForge, is a fermentation platform that uses genetically recoded organisms (GROs) to manufacture peptide therapeutics — including DPPIV-resistant GLP-1 agonists and candidates for liver fibrosis and cardiometabolic disease — as a scalable, sustainable alternative to solid-phase peptide synthesis (SPPS). The IP base is anchored by exclusive licenses from MRC LMB, most recently including the tRNA Display technology licensed in June 2025.

The company's commercial model is B2B and enterprise-oriented, targeting large and mid-size pharmaceutical companies as the primary segment and biotech / life sciences companies as a secondary segment. Go-to-market is executed through direct field sales and strategic partnerships rather than self-serve or consumer channels. Named collaborations include RxCelerate (biologic therapeutic candidates, announced November 2025), the Ellison Institute's Generative Biology Institute (programmable biology, October 2025), Camena Bioscience and the Max-Planck Institute (ARIA-funded synthetic chloroplast genomes, August 2025), and CPI (peptide manufacturing process development). Revenue is expected to come from three streams: platform licensing and partnerships, out-licensing or sale of proprietary biologic candidates, and fermentation-based peptide manufacturing, none of which have produced commercial revenue to date.

Constructive Bio is pre-revenue and venture-backed, having raised approximately $75M in total: a $15M seed in August 2022 led by Ahren, and a $58M Series A in September 2024 led by Ahren, OMX Ventures, and Paladin Capital Group with participation from Fine Structure Ventures, ND Capital, and Jonathan Milner. The team is approximately 30 people headquartered at the 11,000 sq ft "The Recodery" facility in Whittlesford, Cambridge. The leadership team combines scientific founders (Jason Chin as CSO), operational executives (Ola Wlodek as CEO, Solange Bullukian as CFO, Paul Wallace as CBO, Linda Ramirez-Eaves as CLO), and a board that includes Nobel Laureate Sir Gregory Winter and biopharma operator Jim Weissman. Recognition includes the 2026 Heinrich Wieland Prize, the 2025 SynBioBeta Impact Award, and inclusion as a Nature Biotechnology Editor's Pick.

Constructive Bio firmographics

Firmographics
Name
Constructive Bio
Legal name
Constructive Biology Limited
Website
https://constructive.bio
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Short description
Constructive Bio is a Cambridge, UK synthetic biology company that rewrites genetic codes via genetically recoded organisms to manufacture peptide and protein therapeutics containing non-canonical amino acids. It serves pharmaceutical and biotech customers through its BioForge fermentation platform, platform licensing, and co-development partnerships.
Ownership category
akta.pro rank

Constructive Bio industry classification

Industry
Product category
Synthetic Biology / Peptide Therapeutics Manufacturing
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Synthetic genomics
  • Peptide therapeutics
  • Genetic code expansion
  • Non-canonical amino acids
  • Biologics manufacturing

Where Constructive Bio is headquartered

Location

Headquarters

HQ city
Whittlesford
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Constructive Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Platform Licensing and Partnerships: Revenue anticipated from licensing the synthetic genomics platform and engineered translation machinery to pharmaceutical and biotech partners for drug discovery and development programs, including GLP-1 therapeutics. Partnerships structured as co-development agreements, collaboration fees, and milestone-based payments.
  2. Biologic Therapeutic Candidates: Revenue generation through the development and out-licensing or sale of proprietary biologic therapeutic candidates generated using the platform, including peptides and proteins incorporating non-canonical amino acids.
  3. Fermentation-Based Peptide Manufacturing: Sustainable, fermentation-based manufacturing of peptides and proteins as an alternative to traditional solid-phase peptide synthesis (SPPS), targeting the $80B+ peptide therapeutics market.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Constructive Bio product offering

Product offering

Core offering

Constructive Bio develops a synthetic genomics platform that uses genetically recoded organisms (notably Syn61, the world's first fully synthetic recoded genome) and engineered translation machinery to incorporate non-canonical amino acids into peptides and proteins. Its flagship offering, BioForge, is a fermentation-based manufacturing platform that produces peptide and protein therapeutics at industrial scale as a sustainable alternative to chemical solid-phase peptide synthesis, with co-development partnerships and platform licensing for pharmaceutical and biotech customers.

Product overview

Constructive Bio operates as a platform company built on two integrated technology pillars: Synthetic Genomics (whole-genome synthesis and recoding) and Engineered Translation (non-canonical amino acid incorporation). The flagship product is BioForge, a fermentation platform that manufactures peptide therapeutics with non-canonical amino acids using proprietary recoded organisms. The platform is underpinned by foundational technologies including Syn61 (the world's first fully synthetic recoded genome) and tRNA Display technology. A Partner Portal provides existing partners with project management and document access tools. Together, these products enable the biological production of peptides, proteins, macrocycles, and non-protein polymers with chemistries that natural biology cannot access.

Differentiator

Problem solved

Functional benefit

Products and services

  • BioForge Proprietary fermentation platform that uses engineered organisms with recoded genomes to manufacture peptide therapeutics containing non-canonical amino acids at industrial scale through biological fermentation rather than chemical synthesis. Sold/licensed to pharmaceutical partners.
  • Synthetic Genomics Platform Platform for whole-genome synthesis enabling assembly of large DNA segments exceeding 200 kb with verified sequence accuracy and creation of megabase-scale custom DNA in E. coli, forming the foundation for creating recoded organisms used by pharmaceutical and biotech partners.
  • Engineered Translation Platform Platform for engineered protein translation that incorporates non-canonical amino acids (ncAAs) into peptides and proteins by reprogramming the genetic code of cells, creating biofactories for novel biopolymers. Provided to pharmaceutical and biotech partners for therapeutic development.
  • tRNA Display Technology Exclusively licensed technology from MRC LMB enabling rapid and accurate selection of enzymes (tRNA synthetases) for integrating non-canonical amino acids into peptides and proteins, overcoming a major barrier in protein engineering. Used by Constructive Bio and its partners for therapeutic candidate discovery.
  • Partner Portal Secure partner access portal providing real-time project status and milestone tracking, document library with reports and agreements, and direct support from dedicated project teams. Provided to pharmaceutical and biotech partners engaged in co-development programs.

Quantifiable outcome

  • Platform enables exploration of hundreds of millions of non-canonical amino acid-containing peptide and protein variants for therapeutic discovery.
  • +2 more outcomes

Companies that use Constructive Bio

Customer profile

Segments2 records

Ideal customer profiles2 records

Constructive Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Constructive Bio partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and supporting.

  • RxCeleratecoreStrategic or Co-development Partner · 18 November 2025Strategic partnership with RxCelerate, a specialized biologics contract research organization, for the advancement of biologic therapeutic candidates. RxCelerate provides integrated discovery and preclinical development services, supporting Constructive Bio's pipeline of non-canonical amino acid-containing peptide and protein therapeutics.
  • Ellison Institute's Generative Biology Institute (GBI)coreStrategic or Co-development Partner · 1 October 2025Collaboration with the Ellison Institute's Generative Biology Institute, a leading academic center focused on applying generative and synthetic biology approaches to biomedical research. The partnership leverages combined expertise in synthetic genomics and generative biology for novel therapeutic discovery.
  • Camena BiosciencecoreStrategic or Co-development Partner · 1 August 2025AR
  • Max-Planck InstitutecoreStrategic or Co-development Partner · 1 August 2025Three-party ARIA-funded collaboration between Constructive Bio, Camena Bioscience, and the Max-Planck Institute focused on advancing synthetic genomics and genome synthesis technologies. The partnership combines Constructive Bio's synthetic recoded genome platform, Camena Bioscience's DNA synthesis capabilities, and the Max-Planck Institute's research expertise.
  • CPI (Centre for Process Innovation)supportingStrategic or Co-development PartnerPartnership with CPI, a UK-based technology innovation center, funded by Innovate UK, focused on developing and advancing peptide manufacturing processes. The collaboration supports Constructive Bio's fermentation-based manufacturing capabilities as a sustainable alternative to traditional solid-phase peptide synthesis.

Scale indicators5 records

Recent moves8 records

Expansion highlights7 records

Constructive Bio competitors and assessment

Company assessment

Direct peers

  • Sutro Biopharma: Sutro operates a cell-free protein synthesis platform that incorporates non-canonical amino acids for site-specific conjugation of ADCs and other therapeutics. It is the closest direct peer to Constructive Bio in ncAA-incorporating biologic platforms targeting pharma partners, though Sutro uses a cell-free system rather than recoded organisms.
  • Codexis: Codexis engineers proteins (notably enzymes and biotherapeutics) using directed evolution and platform approaches sold into pharma and industrial biotech customers. It is comparable to Constructive Bio as a protein-engineering platform company monetized through licensing and partnerships, with a similar B2B enterprise model.
  • Synaffix (Lonza): Synaffix licenses site-specific ADC conjugation chemistries, including approaches based on non-canonical amino acid incorporation, and was acquired by Lonza. Its licensing-and-platform model for ncAA-enabled biologics is closely analogous to Constructive Bio's anticipated licensing/partnership motion in the ADC and bioconjugate space.

Broad incumbents

  • Ambrx: Ambrx pioneered site-specific incorporation of non-canonical amino acids into proteins for ADCs and other biologics and was acquired by Johnson & Johnson. As the most clinically advanced ncAA-biologics platform, it is the benchmark Constructive Bio must beat on clinical and commercial proof points, even though Ambrx is now embedded in a much larger pharma.
  • Ginkgo Bioworks: Ginkgo is a large, publicly listed synthetic biology platform company offering organism engineering services across pharma, agriculture, and industrial biotech. It is a broader incumbent comparable to Constructive Bio on the 'engineered organism as a service' axis, though its scope and capital base are far larger.
  • Twist Bioscience: Twist provides high-throughput DNA synthesis that underpins synthetic biology workflows. Constructive Bio's CONEXER genome synthesis platform competes with and depends on suppliers like Twist; the two are comparable as DNA/gene synthesis infrastructure providers serving biotech customers.

Emerging players

  • Generate Biomedicines: Generate applies generative AI and machine learning to design novel protein therapeutics, sitting at the intersection of computational biology and biologics discovery. It is comparable to Constructive Bio as an emerging platform company creating new therapeutic proteins, but with an AI-driven rather than genome-recoding approach.
  • Cradle Bio: Cradle uses AI/ML to engineer proteins and biologics, offering a software-and-services platform for protein design. It overlaps with Constructive Bio on the 'novel therapeutic protein design' axis but does not compete on the fermentation/ncAA manufacturing layer.
  • Camena Bioscience: Camena is a DNA synthesis company and an actual ARIA-funded collaboration partner of Constructive Bio. It is a relevant emerging peer because both companies operate at the synthetic DNA / genome synthesis infrastructure layer feeding into engineered organisms.

Regional players

  • Crinetics Pharmaceuticals: Crinetics is a US-based clinical-stage peptide therapeutics company focused on endocrine and metabolic diseases including GLP-1-related targets. While not a platform peer, it is relevant as a downstream comparability point for the peptide therapeutic indications Constructive Bio's BioForge is targeting.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Constructive Bio social profiles

Digital presence

Constructive Bio compliance and trust

Trust signal

Compliance2 records

Constructive Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Constructive Bio leadership team

Management profile

Number of profiles

Profiles15 records

Constructive Bio funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Constructive Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Constructive Bio

What does Constructive Bio do?

Constructive Bio develops a synthetic genomics platform that uses genetically recoded organisms (notably Syn61, the world's first fully synthetic recoded genome) and engineered translation machinery to incorporate non-canonical amino acids into peptides and proteins. Its flagship offering, BioForge, is a fermentation-based manufacturing platform that produces peptide and protein therapeutics at industrial scale as a sustainable alternative to chemical solid-phase peptide synthesis, with co-development partnerships and platform licensing for pharmaceutical and biotech customers.

Is Constructive Bio a public or private company?

Constructive Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Constructive Bio founded?

Constructive Bio was founded in 2021. It employs 51 to 100 people.

Where is Constructive Bio based?

Constructive Bio is headquartered in Whittlesford, United Kingdom, in the Europe region.

How does Constructive Bio make money?

Three revenue lines are on record. Platform Licensing and Partnerships are the primary driver. The others are biologic Therapeutic Candidates and fermentation-Based Peptide Manufacturing.

Who are Constructive Bio's main competitors?

Direct peers on record are Sutro Biopharma, Codexis and Synaffix (Lonza). Broad incumbents are Ambrx, Ginkgo Bioworks and Twist Bioscience. Emerging players are Generate Biomedicines, Cradle Bio and Camena Bioscience. Crinetics Pharmaceuticals is listed as a regional player.

Does Constructive Bio have an API?

No public API is recorded for Constructive Bio.

What industry is Constructive Bio in?

Constructive Bio's product category is Synthetic Biology / Peptide Therapeutics Manufacturing. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development), with a secondary code of HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SynBioBetaFrom Genome Writing to Novel Polymers: Constructive Bio's and Jason Chin’s Bold Vision for Engineered BiologyConstructive Bio, founded by Jason Chin, unveiled advances in genome writing and engineered translation at SynBioBeta 2025, showcasing the Syn57 E. coli strain with a compressed genetic code. The company is leveraging these recoded organisms to biomanufacture novel polymers and enhanced therapeutic molecules, including improved treatments for diabetes and weight loss. These innovations aim to provide evolutionary stability and viral resistance while enabling the scalable production of non-natural materials.Business Wire BlogConstructive Bio Founder and Chief Scientific Officer, Professor Jason Chin, Named the 2026 Heinrich Wieland Prize RecipientProfessor Jason Chin, founder and Chief Scientific Officer of Constructive Bio, has been named the 2026 Heinrich Wieland Prize recipient by the Boehringer Ingelheim Stiftung, one of Europe's most prestigious honours for fundamental life sciences research. The award recognizes his pioneering work in genetic code expansion, which enables cells to biosynthesize unnatural proteins and polymers, with applications in next-generation therapeutics including DPPIV-resistant GLP-1 agonists. Constructive Bio, which Chin founded in 2022 to commercialize these advances, has achieved multi-gram-per-litre scale fermentation of non-canonical amino acid products and is positioning the technology as transformative for pharmaceutical discovery and manufacturing.FinancialContent Business PageConstructive Bio Founder and Chief Scientific Officer, Professor Jason Chin, Named the 2026 Heinrich Wieland Prize RecipientProfessor Jason Chin, founder and Chief Scientific Officer of Constructive Bio, has been named the 2026 Heinrich Wieland Prize recipient by the Boehringer Ingelheim Stiftung, one of Europe's most prestigious honors for fundamental research in the life sciences. The prize recognizes his pioneering work in genetic code expansion technology, which enables cells to biosynthesize unnatural proteins and polymers with properties absent in nature—a methodology that has become the most widely used approach globally for creating non-natural proteins. Constructive Bio, founded in 2022 to commercialize these advances, is applying the technology to pharmaceutical discovery and manufacturing, including complex molecules such as GLP-1 agonists.MorningstarConstructive Bio Founder and Chief Scientific Officer, Professor Jason Chin, Named the 2026 Heinrich Wieland Prize RecipientProfessor Jason Chin, founder and CIO of Constructive Bio, received the 2026 Heinrich Wieland Prize for his genetic-code-expansion technology. The award recognizes his work on synthetic bacterial genomes that enable biosynthesis of unnatural proteins, now applied to therapeutics like GLP-1s.Business WeeklyConstructive Bio adds Weissman to world-class boardConstructive Bio has appointed Jim Weissman to its board of directors as it advances the application of its genetic engineering platform for pharmaceutical manufacturing. Weissman brings extensive experience in scaling biotechnology platforms and establishing industry partnerships, having previously played a key role at Dicerna Pharmaceuticals prior to its acquisition by Novo Nordisk. The company aims to utilize this leadership addition to commercialize its technology for producing complex therapeutics like GLP-1s more sustainably.GenengnewsFrom Colossal to Chickens: The Scientists Behind Neion Bio’s Biologics PlatformNeion Bio, co-founded by Dimi Kellari and Sam Levin, is re-engineering eggs to produce drugs in chickens, with Sven Bocklandt and James Kehler joining as CSO and head of avian sciences. The company uses CRISPR to insert therapeutic proteins into egg white, citing Kanuma as a precedent. Challenges include scalability, cost, and biological variability.BioIndustry AssociationBiosolutions: Engineering a sustainable future, a path to net zero and economic resilienceIn this blog post, Linda Bedenik of the BioIndustry Association (BIA) argues that Biosolutions — technologies powered by engineering biology, AI, genomics, and advanced automation — represent a powerful and scalable pathway to address global challenges including climate change, pollution, and unsustainable industry practices. The article identifies four key application areas (novel food/agriculture, biobased chemicals and materials, environmental pollution remediation, and advanced biofuels), profiles four UK innovator companies (Resurrect Bio, Twig, Epoch Biodesign, and Constructive Bio), and argues that the UK risks missing its opportunity to be a world leader without coordinated policy action on regulation, scale-up infrastructure, and long-term finance.Built InHead of Bioprocess - Constructive BioConstructive Bio, a biotechnology startup based in Cambridge, secured $58 million in Series A funding. The company is developing sustainable materials and therapeutics using genetically engineered cells.